Supplementary Table 4.
Multivariate Model for Death Using AST Excluding 46 Patients Without Follow-Up Evaluation
| Variables | OR | 95% CI | P value |
|---|---|---|---|
| Age | 1.1 | 1.0–1.1 | <.0001 |
| Sex | 1.6 | 1.0–2.6 | .05 |
| Race | 0.8 | 0.4–1.4 | .7 |
| BMI | 1.0 | 0.9–1.0 | .8 |
| Hypertension | 0.9 | 0.5–1.8 | .8 |
| Congestive heart failure | 0.9 | 0.5–1.6 | .8 |
| Chronic lung disease | 0.6 | 0.4–1.1 | .1 |
| Diabetes | 1.0 | 0.6–1.6 | 1.0 |
| Pre-existing liver disease | 0.8 | 0.3–2.1 | .6 |
| Vasopressor | 5.1 | 2.8–9.4 | <.0001 |
| Tocilizumab use | 1.5 | 0.8–2.7 | .1 |
| Hyperinflammatory | 1.5 | 0.9–2.7 | .1 |
| Hypercoagulable | 1.5 | 0.9–2.5 | .1 |
| ALT >5× ULN | 1.2 | 0.5–2.6 | .6 |
| Steroids | 1.9 | 1.1–3.2 | .01 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; OR, odds ratio; ULN, upper limit of normal.